School of Global Health, Chinese Centre for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China.
Pan African University Life and Earth Sciences Institute (PAULESI), University of Ibadan, Ibadan, Nigeria.
Infect Dis Poverty. 2023 Apr 24;12(1):43. doi: 10.1186/s40249-023-01086-z.
Coronavirus disease 2019 (COVID-19) can involve persistence, sequelae, and other clinical complications that last weeks to months to evolve into long COVID-19. Exploratory studies have suggested that interleukin-6 (IL-6) is related to COVID-19; however, the correlation between IL-6 and long COVID-19 is unknown. We designed a systematic review and meta-analysis to assess the relationship between IL-6 levels and long COVID-19.
Databases were systematically searched for articles with data on long COVID-19 and IL-6 levels published before September 2022. A total of 22 published studies were eligible for inclusion following the PRISMA guidelines. Analysis of data was undertaken by using Cochran's Q test and the Higgins I-squared (I) statistic for heterogeneity. Random-effect meta-analyses were conducted to pool the IL-6 levels of long COVID-19 patients and to compare the differences in IL-6 levels among the long COVID-19, healthy, non-postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (non-PASC), and acute COVID-19 populations. The funnel plot and Egger's test were used to assess potential publication bias. Sensitivity analysis was used to test the stability of the results.
An increase in IL-6 levels was observed after SARS-CoV-2 infection. The pooled estimate of IL-6 revealed a mean value of 20.92 pg/ml (95% CI = 9.30-32.54 pg/ml, I = 100%, P < 0.01) for long COVID-19 patients. The forest plot showed high levels of IL-6 for long COVID-19 compared with healthy controls (mean difference = 9.75 pg/ml, 95% CI = 5.75-13.75 pg/ml, I = 100%, P < 0.00001) and PASC category (mean difference = 3.32 pg/ml, 95% CI = 0.22-6.42 pg/ml, I = 88%, P = 0.04). The symmetry of the funnel plots was not obvious, and Egger's test showed that there was no significant small study effect in all groups.
This study showed that increased IL-6 correlates with long COVID-19. Such an informative revelation suggests IL-6 as a basic determinant to predict long COVID-19 or at least inform on the "early stage" of long COVID-19.
2019 年冠状病毒病(COVID-19)可涉及持续存在、后遗症和其他临床并发症,持续数周到数月,进而发展为长新冠。探索性研究表明白细胞介素 6(IL-6)与 COVID-19 相关;然而,IL-6 与长新冠的相关性尚不清楚。我们设计了一项系统评价和荟萃分析,以评估 IL-6 水平与长新冠之间的关系。
系统检索了截至 2022 年 9 月发表的关于长新冠和 IL-6 水平的文章数据。根据 PRISMA 指南,共有 22 项符合纳入标准的研究。使用 Cochran's Q 检验和 Higgins I 平方(I)统计量评估异质性,对数据进行分析。采用随机效应荟萃分析来汇总长新冠患者的 IL-6 水平,并比较长新冠、健康人群、非严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染后后遗症(非 PASC)和急性 COVID-19 人群中 IL-6 水平的差异。使用漏斗图和 Egger 检验评估潜在的发表偏倚。进行敏感性分析以检验结果的稳定性。
在 SARS-CoV-2 感染后观察到 IL-6 水平升高。荟萃分析的 IL-6 汇总估计值为 20.92pg/ml(95%置信区间:9.30-32.54pg/ml,I=100%,P<0.01),用于长新冠患者。森林图显示长新冠患者的 IL-6 水平较高,与健康对照组相比(平均差异=9.75pg/ml,95%置信区间:5.75-13.75pg/ml,I=100%,P<0.00001)和 PASC 类别(平均差异=3.32pg/ml,95%置信区间:0.22-6.42pg/ml,I=88%,P=0.04)。漏斗图的对称性不明显,Egger 检验显示所有组均无显著的小样本效应。
本研究表明,IL-6 水平升高与长新冠相关。这一有启发性的发现表明 IL-6 是预测长新冠或至少提示长新冠“早期”的基本决定因素。